# Luspatercept PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/luspatercept

> The next catalyst for luspatercept, sponsored by BRISTOL MYERS SQUIBB CO (BMY), is its topline data readout, Jul to Oct 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | luspatercept |
| Codes | ACE-536, BMS-986346 |
| Sponsor | BRISTOL MYERS SQUIBB CO (BMY) https://sec-api.dev/companies/bmy/catalysts |
| Indications | Myelodysplastic Syndromes (MDS), [Anemia](https://sec-api.dev/indications/anemia), [Myelodysplastic Syndromes](https://sec-api.dev/indications/myelodysplastic-syndromes), [Beta-thalassemia](https://sec-api.dev/indications/beta-thalassemia), Myeloproliferative Disorders |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### May 26, 2025: primary completion

- Status: completed. Date confidence: exact. Stage: 3. Indication: Myeloproliferative Disorders; Myelofibrosis; Primary Myelofibrosis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT04717414 (An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-05-26 (ACTUAL); Lead Sponsor Celgene; Results First Posted 2026-07-16." https://clinicaltrials.gov/study/NCT04717414

### August 1, 2025: primary completion

- Status: completed. Date confidence: exact. Stage: 2. Indication: Beta-thalassemia.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05567458 (A Study to Evaluate Luspatercept (ACE-536) in Chinese Participants Who Require Regular Red Blood Cell Transfusions Due to Beta (β)-Thalassemia.): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2025-08-01 (ACTUAL); Lead Sponsor Bristol-Myers Squibb." https://clinicaltrials.gov/study/NCT05567458

### October 1, 2025: primary completion

- Status: completed. Date confidence: exact. Stage: 3. Indication: Myelodysplastic Syndromes.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06045689 (A Study to Assess Luspatercept in Lower-risk Myelodysplastic Syndrome Participants): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-10-01 (ACTUAL); Lead Sponsor Bristol-Myers Squibb." https://clinicaltrials.gov/study/NCT06045689

### July 16, 2026: topline data readout

- Status: completed. Date confidence: exact. Stage: 3. Indication: Myeloproliferative Disorders; Myelofibrosis; Primary Myelofibrosis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT04717414 (An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-05-26 (ACTUAL); Lead Sponsor Celgene; Results First Posted 2026-07-16." https://clinicaltrials.gov/study/NCT04717414?tab=results

### Jul to Oct 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Anemia.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05664737 (A Study to Determine the Efficacy and Safety of Luspatercept in Adult Participants and to Evaluate the Safety and Pharmacokinetics in and Adolescent Participants With Alpha (α)-Thalassemia): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-07-16 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." https://clinicaltrials.gov/study/NCT05664737

### July 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Anemia.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05664737 (A Study to Determine the Efficacy and Safety of Luspatercept in Adult Participants and to Evaluate the Safety and Pharmacokinetics in and Adolescent Participants With Alpha (α)-Thalassemia): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-07-16 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." https://clinicaltrials.gov/study/NCT05664737

### Jan to Apr 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Beta-Thalassemia.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT04143724 (Study of Safety & PK of Luspatercept (ACE-536) in Pediatric Participants With Beta (β)-Thalassemia): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-01-31 (ESTIMATED); Lead Sponsor Celgene." https://clinicaltrials.gov/study/NCT04143724

### January 2028: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Beta-Thalassemia.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT04143724 (Study of Safety & PK of Luspatercept (ACE-536) in Pediatric Participants With Beta (β)-Thalassemia): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-01-31 (ESTIMATED); Lead Sponsor Celgene." https://clinicaltrials.gov/study/NCT04143724

### Mar to Jun 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Myelodysplastic Syndromes.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05949684 (ELEMENT-MDS: A Study to Compare the Efficacy and Safety of Luspatercept in Participants With Myelodysplastic Syndrome (MDS) and Anemia Not Receiving Blood Transfusions): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-03-24 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." https://clinicaltrials.gov/study/NCT05949684

### March 2028: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Myelodysplastic Syndromes.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05949684 (ELEMENT-MDS: A Study to Compare the Efficacy and Safety of Luspatercept in Participants With Myelodysplastic Syndrome (MDS) and Anemia Not Receiving Blood Transfusions): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-03-24 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." https://clinicaltrials.gov/study/NCT05949684

### May to Aug 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT04064060 (A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-05-12 (ESTIMATED); Lead Sponsor Celgene." https://clinicaltrials.gov/study/NCT04064060

### May 2028: primary completion

- Status: scheduled. Date confidence: month. Stage: 3.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT04064060 (A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-05-12 (ESTIMATED); Lead Sponsor Celgene." https://clinicaltrials.gov/study/NCT04064060

## Same indication

- [Decitabine](https://sec-api.dev/pdufa/decitabine) (NVS)
- [Elritercept](https://sec-api.dev/pdufa/elritercept) (TAK)
- [OJJAARA (momelotinib)](https://sec-api.dev/pdufa/momelotinib) (GSK)
- [Oral azacitidine](https://sec-api.dev/pdufa/oral-azacitidine) (BMY)
- [Evrenzo® (roxadustat)](https://sec-api.dev/pdufa/roxadustat) (KYNB)
- [Tebapivat](https://sec-api.dev/pdufa/tebapivat) (AGIO)

Calendar months: [July 2027](https://sec-api.dev/fda-calendar/2027-07), [January 2028](https://sec-api.dev/fda-calendar/2028-01), [March 2028](https://sec-api.dev/fda-calendar/2028-03), [May 2028](https://sec-api.dev/fda-calendar/2028-05)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/luspatercept.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Luspatercept PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/luspatercept

```bibtex
@misc{secapidev_pdufa_luspatercept_20261116,
  title        = {Luspatercept PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/luspatercept}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_luspatercept_20261116","title":"Luspatercept PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/luspatercept","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
